trastuzumab deruxtecan + durvalumab + cisplatin

This drug is a **combination therapy** consisting of three agents: trastuzumab deruxtecan (T-DXd), durvalumab, and cisplatin. - **Trastuzumab deruxtecan** is an antibody-drug conjugate (ADC) targeting HER2 (human epidermal growth factor receptor 2). It has a humanized anti-HER2 monoclonal antibody linked to a topoisomerase I inhibitor, delivering targeted cytotoxicity to HER2-expressing tumor cells by delivering its payload after internalization[6][1]. - **Durvalumab** is a monoclonal antibody that targets the immune checkpoint PD-L1, blocking its interaction with PD-1 and CD80 to enhance the antitumor immune response. - **Cisplatin** is a platinum-based chemotherapy that causes DNA crosslinking and apoptosis in rapidly dividing cells. This combination is being investigated mainly for use in HER2-positive non-squamous non-small cell lung cancer and is undergoing clinical trials for safety, tolerability, and efficacy as first-line treatment[1][9][5]. The therapy aims to combine targeted anti-HER2 therapy, immune checkpoint inhibition, and cytotoxic chemotherapy for potential synergistic effects.

Other names

HER2-directed antibody-drug conjugate + anti-PD-L1 antibody + platinum chemotherapyT-DXd + durvalumab + cisplatin